Losartan Potassium
Product Images NDC 53217-369

6 FDA label images from Aidarex Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53217-369). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Losartan Potassium 25mg 1)

Chemical Structure (Losartan Potassium 25mg 1)
Chemical structure of Losartan Potassium showing its molecular formula with rings, side chains, and potassium ion (K+) as part of its composition.*
FDA Label Image

Figure 1 (Losartan Potassium 25mg 2)

Figure 1 (Losartan Potassium 25mg 2)
A line graph comparing the percentage of patients with primary endpoints over study months for Atenolol (dotted line) versus Losartan Potassium (solid line). The graph shows data up to 66 months and indicates an adjusted risk reduction of 13% with Losartan Potassium, with a p-value of 0.021.*
FDA Label Image

Figure 2 (Losartan Potassium 25mg 3)

Figure 2 (Losartan Potassium 25mg 3)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months for Atenolol and Losartan Potassium. The graph shows adjusted risk reduction of 25%, with Atenolol represented by a dotted line and Losartan Potassium by a solid line, indicating patient outcomes over approximately 66 months.*
FDA Label Image

Figure 3 (Losartan Potassium 25mg 4)

Figure 3 (Losartan Potassium 25mg 4)
A comparative forest plot chart showing primary endpoint events within demographic subgroups for Losartan Potassium versus Atenolol. The chart displays hazard ratios with 95% confidence intervals, event rates, and patient counts across age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD) categories. Symbols vary by sample size and indicate whether results favor Losartan Potassium or Atenolol.*
FDA Label Image

Figure 4 (Losartan Potassium 25mg 5)

Figure 4 (Losartan Potassium 25mg 5)
A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and placebo groups. The solid line represents Losartan Potassium, and the dotted line represents placebo. The chart shows a risk reduction of 16.1% with a p-value of 0.022.*
FDA Label Image

53217-0369_losartan-pot_25mg (Losartan Potassium 25mg 6)

53217-0369_losartan-pot_25mg (Losartan Potassium 25mg 6)
Losartan Potassium, USP 25 mg tablets, packaged in a white round tablet bottle containing 30 film-coated tablets. The label includes the generic drug name, dosage strength, quantity, and the labeler Aidarex Pharmaceuticals LLC. Packaging and distributed by Zhejiang Huahai Pharmaceutical Co., Ltd. Barcodes and lot, expiration, and NDC numbers are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.